Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1990 1
1992 1
2002 1
2004 2
2006 1
2007 3
2008 4
2009 3
2010 6
2011 8
2012 10
2013 7
2014 7
2015 8
2016 16
2017 6
2018 8
2019 23
2020 22
2021 23
2022 17
2023 23
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Results by year

Filters applied: . Clear all
Page 1
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Clinical Trial.
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: glas m. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression.
Ratliff M, Karimian-Jazi K, Hoffmann DC, Rauschenbach L, Simon M, Hai L, Mandelbaum H, Schubert MC, Kessler T, Uhlig S, Dominguez Azorin D, Jung E, Osswald M, Solecki G, Maros ME, Venkataramani V, Glas M, Etminan N, Scheffler B, Wick W, Winkler F. Ratliff M, et al. Among authors: glas m. Neuro Oncol. 2023 Dec 8;25(12):2150-2162. doi: 10.1093/neuonc/noad109. Neuro Oncol. 2023. PMID: 37335907
[Biomarkers in cardio-oncology patients].
Totzeck M, Glas M, Rassaf T. Totzeck M, et al. Among authors: glas m. Internist (Berl). 2020 Nov;61(11):1114-1119. doi: 10.1007/s00108-020-00883-0. Internist (Berl). 2020. PMID: 33025124 Review. German.
Theranostics in Neurooncology: Heading Toward New Horizons.
Tolboom N, Verger A, Albert NL, Fraioli F, Guedj E, Traub-Weidinger T, Morbelli S, Herrmann K, Zucchetta P, Plasschaert SLA, Yakushev I, Weller M, Glas M, Preusser M, Cecchin D, Barthel H, Van Weehaeghe D. Tolboom N, et al. Among authors: glas m. J Nucl Med. 2024 Feb 1;65(2):167-173. doi: 10.2967/jnumed.123.266205. J Nucl Med. 2024. PMID: 38071569
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, Barbato F, Lueckerath K, Kasper S, Nader M, Schildhaus HU, Kesch C, von Tresckow B, Hanoun C, Hautzel H, Aigner C, Glas M, Stuschke M, Kümmel S, Harter P, Lugnier C, Uhl W, Niedergethmann M, Hadaschik B, Grünwald V, Siveke JT, Herrmann K, Fendler WP. Hirmas N, et al. Among authors: glas m. J Nucl Med. 2023 May;64(5):711-716. doi: 10.2967/jnumed.122.264689. Epub 2022 Dec 29. J Nucl Med. 2023. PMID: 36581374 Free article. Review.
Primary CNS lymphoma: a clinician's guide.
Schäfer N, Glas M, Herrlinger U. Schäfer N, et al. Among authors: glas m. Expert Rev Neurother. 2012 Oct;12(10):1197-206. doi: 10.1586/ern.12.120. Expert Rev Neurother. 2012. PMID: 23082736 Review.
Therapy of leptomeningeal metastasis in solid tumors.
Mack F, Baumert BG, Schäfer N, Hattingen E, Scheffler B, Herrlinger U, Glas M. Mack F, et al. Among authors: glas m. Cancer Treat Rev. 2016 Feb;43:83-91. doi: 10.1016/j.ctrv.2015.12.004. Epub 2015 Dec 24. Cancer Treat Rev. 2016. PMID: 26827696 Review.
BRMS1 in Gliomas-An Expression Analysis.
Feldheim J, Kessler AF, Feldheim JJ, Schmitt D, Oster C, Lazaridis L, Glas M, Ernestus RI, Monoranu CM, Löhr M, Hagemann C. Feldheim J, et al. Among authors: glas m. Cancers (Basel). 2023 May 25;15(11):2907. doi: 10.3390/cancers15112907. Cancers (Basel). 2023. PMID: 37296870 Free PMC article.
KDM5B predicts temozolomide-resistant subclones in glioblastoma.
Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull HH, Cima I, Berger P, Dobersalske C, Langer S, Meyer L, Dujardin P, Kebir S, Glas M, Blau T, Keyvani K, Rauschenbach L, Sure U, Roesch A, Grüner BM, Scheffler B. Ullrich V, et al. Among authors: glas m. iScience. 2023 Dec 3;27(1):108596. doi: 10.1016/j.isci.2023.108596. eCollection 2024 Jan 19. iScience. 2023. PMID: 38174322 Free PMC article.
184 results